Skip to main
ACAD
ACAD logo

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 27%
Buy 33%
Hold 37%
Sell 0%
Strong Sell 3%

Bulls say

ACADIA Pharmaceuticals Inc demonstrates a positive outlook driven by a robust growth trajectory, highlighted by a fiscal year 2024 total sales increase of 32% year-over-year, underscoring effective strategies to enhance brand awareness for NUPLAZID and DAYBUE, which are critical to its revenue generation. The company's solid market position is further reinforced by strong commercial metrics for DAYBUE, including improved patient adherence and an expanding diagnosed population, with fourth-quarter revenue of $97 million exceeding expectations. Additionally, ACADIA's financial stability is strengthened by a significant cash position of $756 million, enabling the company to support its commercial operations and advance its product pipeline in the neurology sector.

Bears say

ACADIA Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock. Key issues include anticipated declines in net pricing for DAYBUE due to Medicare Part D redesign, coupled with negative sentiment surrounding NUPLAZID leading to reduced patient starts and sales growth. Additionally, commercial risks are highlighted, particularly concerning NUPLAZID's market performance, potentially slower uptake of DAYBUE, and uncertainties regarding the performance of other pipeline candidates, which could hinder revenue growth and overall business performance.

ACADIA Pharma (ACAD) has been analyzed by 30 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 33% recommend Buy, 37% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 30 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.